Purpose: This was a randomized, double-blind study comparing the safety and patient acceptability of 10% Gammagard-SD to a licensed IGIV product, 10%Gamimune.-N. Background: Intravenous gammaglobulin (IGIV) preparations have been tested in the US since 1975 and ten have been licensed since 1981, seven of which are currently available. The efficacy of IGIV in preventing infections in patients with primary disorders of humoral immunity is well accepted, though it has never been subjected to a controlled double-blind study. A study comparing IGIV to placebo would be considered unethical, though it is possible to compare new products to those that have been licensed for use. In the past several years efforts have focused on developing products with increased safety, especially with regard to the risk of transmitting viral infections such as Hepatitis C. This study proposes to compare the safety and efficacy of a newly licensed 10% solvent/detergent IGIV preparation, Gammagard-SD to a licensed preparation, 10% Gamimune.- N. Gammagard-SD is a sterile, preservative-free, lyophilized preparation of unmodified human polyvalent immunoglobulins manufactured by Baxter Healthcard Corporation, Hyland division.. It is prepared from ISG made from a pool of at least 1000 donors. Donors are tested for HIV, HBsAg, Hepatitis C antibody, and increased levels of ALT before being accepted into the pool. The ISG is prepared by the same Cohn fractionation process used for all of the currently licensed products. The Cohn fraction III supernatant is subjected to a viral inactivation step consisting of treatment with solvent (0.3% tri-n-butyl phosphate) and two detergents, oxtoxynol 9 (Triton X-100) and polysorbate 80 (Tween 80) using a process similar to that developed in the New York Blood Center and currently used for one other licensed IGIV preparation and other blood products. After addition of the solvent and detergents the solution is treated to remove all but trace amounts of the additives. The final lyophilized product, when reconstituted to 5% IgG, contains 0.3 gm/dl human albumin, 0.15 M NaCl, 0.11 M dextrose, 0.3 M glycine, 0.2 g/dl polyethylene glycol, and residual levels of IgM and IgA. Gammagard-SD has one of the lowest IgA levels of any product.
| Askie, Lisa M; Darlow, Brian A; Finer, Neil et al. (2018) Association Between Oxygen Saturation Targeting and Death or Disability in Extremely Preterm Infants in the Neonatal Oxygenation Prospective Meta-analysis Collaboration. JAMA 319:2190-2201 |
| Srinivasan, Lakshmi; Page, Grier; Kirpalani, Haresh et al. (2017) Genome-wide association study of sepsis in extremely premature infants. Arch Dis Child Fetal Neonatal Ed 102:F439-F445 |
| Denson, Lee A; McDonald, Scott A; Das, Abhik et al. (2017) Early Elevation in Interleukin-6 is Associated with Reduced Growth in Extremely Low Birth Weight Infants. Am J Perinatol 34:240-247 |
| James, Jennifer; Munson, David; DeMauro, Sara B et al. (2017) Outcomes of Preterm Infants following Discussions about Withdrawal or Withholding of Life Support. J Pediatr 190:118-123.e4 |
| Younge, Noelle; Goldstein, Ricki F; Bann, Carla M et al. (2017) Survival and Neurodevelopmental Outcomes among Periviable Infants. N Engl J Med 376:617-628 |
| Archer, Stephanie Wilson; Carlo, Waldemar A; Truog, William E et al. (2016) Improving publication rates in a collaborative clinical trials research network. Semin Perinatol 40:410-417 |
| Ahmed, Zuhayer; Prasad, Indrajit; Rahman, Hafizur et al. (2016) A Male with Extreme Subcutaneous Insulin Resistance: A Case Report. Rom J Diabetes Nutr Metab Dis 23:209-213 |
| Phelps, Dale L; Ward, Robert M; Williams, Rick L et al. (2016) Safety and pharmacokinetics of multiple dose myo-inositol in preterm infants. Pediatr Res 80:209-17 |
| Barroso, Julie; Leserman, Jane; Harmon, James L et al. (2015) Fatigue in HIV-Infected People: A Three-Year Observational Study. J Pain Symptom Manage 50:69-79 |
| Stafford-Smith, Mark; Li, Yi-Ju; Mathew, Joseph P et al. (2015) Genome-wide association study of acute kidney injury after coronary bypass graft surgery identifies susceptibility loci. Kidney Int 88:823-32 |
Showing the most recent 10 out of 128 publications
